High Level of COP1 Expression is Associated with Poor Prognosis in Primary Gastric Cancer

Yuan-Fang Li, Dandan Wang, Bai-wei Zhao, Wei Wang, Chun-yu Huang, Yong-ming Chen, Zheng Yan, Rajiv Prasad Keshari, Jian-chuan Xia, Zhi-Wei ZhouInternational Journal of Biological Sciences 2012 · DOI

Abstract

COP1 (constitutive photomorphogenic 1) is a p53-targeting E3 ubiquitin ligase. Recent studies have identified that COP1 is overexpressed in several cancer types, promoting tumor progression. This study investigated the expression and prognostic value of COP1 in primary gastric cancer. Using real-time quantitative PCR and western blotting on paired cancerous and matched adjacent noncancerous gastric tissues, the researchers found high COP1 mRNA and protein expression in tumor tissues. A significant negative correlation was observed between COP1 and p53 expression. Immunohistochemical analysis of 401 gastric cancer tissue blocks revealed that high COP1 expression significantly correlated with advanced T, M, and TNM stages, as well as poor overall survival. Cox regression analysis identified COP1 as an independent predictor of survival, suggesting its potential as a prognostic marker and therapeutic target.

Introduction

Gastric cancer remains a leading cause of cancer-related mortality worldwide, often characterized by late-stage diagnosis and a lack of precise prognostic indicators. The progression of this malignancy is driven by a complex interplay of oncogene activation and tumor suppressor inactivation. COP1 (also known as RFWD2), an E3 ubiquitin ligase, has emerged as a significant player in oncogenesis due to its ability to target the tumor suppressor p53 for degradation. While COP1's oncogenic role has been suggested in breast and ovarian cancers, its specific impact on gastric cancer prognosis and its clinical relationship with p53 required rigorous validation.

Methods

The researchers employed a multi-tiered experimental approach using samples from Sun Yat-sen University Cancer Center. The study utilized two primary patient cohorts: a fresh tissue cohort of 40 paired samples for immediate molecular analysis (RT-qPCR and Western blotting) and a historical cohort of 401 paraffin-embedded samples for long-term survival analysis. Immunohistochemistry (IHC) was used to map protein distribution and quantify expression levels across the larger cohort. Statistical significance was determined using Kaplan-Meier survival curves and Cox proportional-hazard regression models to evaluate COP1 as an independent prognostic factor.

Results

COP1 Overexpression in Gastric Cancer Tissues

Molecular analysis revealed that COP1 is markedly upregulated in gastric cancer tissues compared to matched adjacent normal tissues. RT-qPCR demonstrated significantly higher mRNA levels in 62.5% of tumor samples (P=0.030). Western blot analysis confirmed these findings at the protein level, showing significant elevation in 54.5% of cases (P=0.008), establishing COP1 as a consistently overexpressed marker in this cancer type.

Relative protein expression of COP1 in gastric cancer (Cancer) and matched adjacent noncancerous tissues (Normal).

Inverse Correlation Between COP1 and p53

A critical insight from this study is the strong negative correlation between COP1 and p53 expression. In clinical samples where COP1 protein levels were high, p53 levels were almost invariably low (r = -0.572, P = 0.005). This provides compelling clinical evidence for the biochemical model in which COP1 facilitates the degradation of the "guardian of the genome," p53, thereby promoting tumor survival and progression.

Negative correlation between COP1 and p53 protein expression in gastric cancer samples.

Clinical Significance and Prognostic Value

High COP1 expression was significantly associated with advanced clinicopathological features, including deeper tumor infiltration (T stage), distant metastasis (M stage), and higher overall TNM stage. Survival analysis demonstrated a stark disparity in outcomes: patients with high COP1 expression had a 5-year overall survival rate of 48.1%, compared to 71.0% for those with low expression (P < 0.001). Multivariate analysis confirmed that COP1 is an independent predictor of poor prognosis, providing information beyond standard staging.

Conclusion

This study establishes COP1 as a key oncogenic driver and a robust prognostic biomarker in gastric cancer. By facilitating p53 degradation, COP1 promotes aggressive tumor behavior and predicts significantly poorer patient survival. These findings suggest that COP1 could serve as a valuable target for novel therapeutic interventions, such as gene therapy or small molecule inhibitors, aimed at restoring p53 function in gastric cancer patients.

Summary updated

Abstract

COP1 (constitutive photomorphogenic 1, also known as RFWD2) is a p53-targeting E3 ubiquitin ligase containing RING-finger, coiled-coil, and WD40-repeat domains. Recent studies have identified that COP1 is overexpressed in several cancer types and that increased COP1 expression promotes cell proliferation, cell transformation, and tumor progression. In the present study, we investigated the expression and prognostic value of COP1 in primary gastric cancer. To investigate the role of the COP1 gene in primary gastric cancer pathogenesis, real-time quantitative PCR and western blotting were performed to examine COP1 expression in paired cancerous and matched adjacent noncancerous gastric tissues. The results revealed high COP1 mRNA (P=0.030) and protein (P=0.008) expression in most tumor-bearing tissues compared with the matched adjacent non-tumor tissues. The correlated protein expression analysis revealed a negative correlation between COP1 and p53 in gastric cancer samples (P=0.005, r=-0.572). Immunohistochemical staining of gastric cancer tissues from the same patient showed a high COP1 expression and a low p53 expression. To further investigate the clinicopathological and prognostic roles of COP1 expression, we performed immunohistochemical analysis of 401 paraffin-embedded gastric cancer tissue blocks. The data revealed that high COP1 expression was significantly correlated with T stage (P=0.030), M stage (P=0.048) and TNM stage (P=0.022). Consistent with these results, we found that high expression of COP1 was significantly correlated with poor survival in gastric cancer patients (P<0.001). Cox regression analyses showed that COP1 expression was an independent predictor of overall survival (P<0.001). Our data suggest that COP1 could play an important role in gastric cancer and might serve as a valuable prognostic marker and potential target for gene therapy in the treatment of gastric cancer.
BibTeX
@article{li2012high,
  author = {Yuan-Fang Li and Dandan Wang and Bai-wei Zhao and Wei Wang and Chun-yu Huang and Yong-ming Chen and Zheng Yan and Rajiv Prasad Keshari and Jian-chuan Xia and Zhi-Wei Zhou},
  title = {{High Level of COP1 Expression is Associated with Poor Prognosis in Primary Gastric Cancer}},
  journal = {International Journal of Biological Sciences},
  year = {2012},
  doi = {10.7150/ijbs.4778},
}
Figure